logo
Plus   Neg
Share
Email

McLaren Racing Announces Multi-year F1 Partnership Extension With Arrow Electronics - Quick Facts

British motor racing team McLaren Racing Ltd. announced Thursday a multi-year extension of its Formula 1 partnership with Arrow Electronics, Inc. (ARW), the technology and innovation business.

The partnership, which started in 2019, will strive to bring services and solutions to the team and their respective networks.

The Arrow Electronics brand will continue to be carried on the McLaren Formula 1 race cars and on the team's 2021 race drivers, Lando Norris and Daniel Ricciardo, as part of a multi-faceted activation program mirroring the IndyCar partnership with Arrow McLaren SP.

McLaren Racing competes in the 2020 FIA Formula 1 World Championship with Lando Norris and Carlos Sainz, and in IndyCar in the US with Pato O'Ward and Felix Rosenqvist.

Arrow Electronics was a key supplier to McLaren and the VentilatorChallengeUK consortium in 2020. The consortium answered the urgent call for additional ventilators in response to the global coronavirus pandemic.

Arrow's contribution with its extensive electronic component-sourcing capability enabled McLaren and the consortium to produce and deliver more than 13,000 medical ventilators - in effect 10 years of ventilator production in 10 weeks - to treat and save lives across the UK and overseas.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Australian government has passed the newly amended Media Bargaining Code in the parliament which requires technology giants Facebook and Google to pay for local Australian news content that is shared on their platforms. Regeneron Pharmaceuticals, Inc. (REGN) Thursday said it stopped enrollment into the placebo group for its Phase 3 trial of REGEN-COV in non-hospitalised patients with COVID-19 as per the recommendations from the Independent Data Monitoring Committee or IDMC. According to the company, the IDMC found... Moderna Inc. (MRNA) Thursday reported a fourth-quarter net loss that widened from last year. But quarterly revenues surged from the previous year, driven by increases in grant revenue and product sales. The company raised its 2021 COVID-19 vaccine manufacturing plan.
Follow RTT